Sunshine Biopharma (OTCBB: SBFM) Management Bets on Lead Anti-Cancer Compound Adva-27a; Taking No Compensation

New York, New York - August 20, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks releases an investor alert on Sunshine Biopharma Inc. (OTCBB: SBFM) reporting on management's unusual commitment to the shareholders; no compensation is currently paid out to the top executives according to Company filings.

Key management including Chairman and CEO, Dr. Steve N. Slilaty Ph.D, Mr. Camille Sebaaly, CFO and Mr. Michele Di Turi, COO do own equity in the company.
Sunshine Biopharma's lead compound, Adva-27a is an effective and highly specific Topoisomerase II (Top2) Inhibitor that has proven effective at killing Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The Company recently reported that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma's lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment. The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal ( Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
Read Investorideas.com Q&A Interview with Mr. Camille Sebaaly, CFO
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
SEC filings: http://finance.yahoo.com/q/sec?s=SBFM+SEC+Filings
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Trading up 9.33%

New York, NY - August 16, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID), trading up over 9% on the day on volume of just under 800,000 at the time of this report. The stock is trading at $0.0164, up 0.0014 or 9.33% as of 1:05PM EDT, with a high of $0.0175.
Yesterday, PositiveID's Chairman and CEO William J. Caragol discussed the $5.7 Billion BioWatch Opportunity in an audio interview with SmallCapVoice.com. http://finance.yahoo.com/news/ positiveids-chairman-ceo- william-j-120000295.html
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, biodefense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Biotech Stock Trading Alert: Sunshine Biopharma (OTCBB: SBFM) Moves 31% on News of Lead Anti-Cancer Compound Adva-27a Manuscript Publication

New York, New York - August 15, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Sunshine Biopharma Inc. (OTCBB:SBFM) following news of its lead anti cancer compound, Adva-27a Manuscript for "PUBLICATION IN A PEER-REVIEWED SCIENTIFIC JOURNAL."

The stock has moved 31% on the news at the time of this report.
The Company reported today that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.
Full news release:
http://www.investorideas.com/CO/SBFM/ news/ 2012/08152.asp
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biodefense Stock News; PositiveID's (OTCBB: PSID) Chairman and CEO William J. Caragol Discusses $5.7 Billion BioWatch Opportunity with SmallCapVoice.com

AUSTIN, Texas - August 15, 2012 - (Investorideas.com Newswire) SmallCapVoice.com, Inc. announced today that a new audio interview with PositiveID Corporation (OTCBB: PSID), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management, is now available. The interview can be heard at http://smallcapvoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
Statements about PositiveID's future expectations, including the likelihood that PositiveID's M-BAND is one of the only technologies capable of addressing the requirements of the BioWatch procurement; the likelihood that M-BAND was designed with a high level of operational flexibility; the likelihood that PositiveID is well positioned to compete for Generation 3 of the BioWatch program and the Company continues to work toward the expected deployment of its bioaerosol detectors; the likelihood that the Company's M-BAND has numerous technology advantages; the likelihood that the value of the BioWatch procurement is estimated at $5.7 billion; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize its bio-threat detection systems for homeland defense, including its M-BAND system; the likelihood that the Company will participate in the BioWatch program; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, and 10-Qs filed on May 14, 2012, November 14, 2011, and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
About PositiveID Corporation OTCBB:PSID)
PositiveID Corporation is an emerging growth developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
CONTACT:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Trilogy Capital Partners, Inc.
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com

PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.com
Visit the company profile: http://www.investorideas.com/CO/PSID/

Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30,2012 . Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and  company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

BI0PHARMA STOCK ALERT: SUNSHINE BIOPHARMA (OTCBB: SBFM) REPORTS SUBMISSION OF AN Adva-27a MANUSCRIPT FOR PUBLICATION IN A PEER-REVIEWED SCIENTIFIC JOURNAL

Montreal, Quebec, Canada - August 15, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.

The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal ( Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
About Sunshine Biopharma Inc. ( OTCBB: SBFM ):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. ( OTCBB: SBFM ) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
Recent CFA commentary:
http://www.investorideas.com/CO/SBFM/news/2012/07301.asp
Published at Investorideas.com Newswire
Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 www.Investorideas.com

OTC Healthcare Stock Alert: Comprehensive Care (OTCBB: CHCR) Six Month Financial Results; Revenues of $36 Million, Earnings of $1.7 Million or $0.02 Per Share

TAMPA, Fla. - August 14, 2012 (Investorideas.com newswire) OTC Healthcare stock alert - Comprehensive Care Corporation (OTCBB: CHCR), a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., reports earnings of $1.7 million for the six months ended June 30, 2012. Earnings per diluted common share were $0.02. This compares to a $3.9 million loss in the first six months of 2011 and a $.07 loss per common share.

The Company announced that operating income for the first half of 2012 totaled $2.1 million compared to an operating loss of $3.1 million in the same period in 2011. While revenues for the first six months declined slightly from $36.8 million in 2011 to $36.0 million in 2012, the cost of revenues decreased 13.9 percent from $35.3 million in 2011 to $30.4 million in the comparable period in 2012.
"The cost saving measures we accomplished earlier this year, with mid-level and senior executives taking salary reductions, and some layoffs, combined with ending contracts that were not profitable for CompCare, are paying rewards. For the first six months of 2012, we were profitable, cash flow positive and were able to increase operating income and reduce our general and administrative expenses from $4.1 million in the first half of 2011 to $2.7 million for the comparable period this year," said Clark Marcus, Chairman and CEO.
"I am especially pleased that our pharmacy management contracts were up 18.9 percent, or $3.1 million, to $19.4 million in the first six months of 2012 compared to the previous year due to a 3.6 percent increase in membership and an 11 percent contract rate increase with the health plan we serve in Puerto Rico. We truly believe our strategies to reduce pharmaceutical costs for our clients will be a key element for our future growth," Mr. Marcus said.
"I am very proud of these financial results and the fact that CompCare's management team has solidified the foundation of the Company, improving it to support our growth. We have added senior level consultants with track records of success and we are dedicated to provide our shareholders continued growth in the future," Mr. Marcus concluded.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Healthcare Stock News: Comprehensive Care Corporation (OTCBB: CHCR) Announces Profitable Six Month Financial Results

TAMPA, Fla. - August 13, 2012 (Investorideas.com newswire) Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., today announced earnings of $1.7 million for the six months ended June 30, 2012. Earnings per diluted common share were $0.02. This compares to a $3.9 million loss in the first six months of 2011 and a $.07 loss per common share.

The Company announced that operating income for the first half of 2012 totaled $2.1 million compared to an operating loss of $3.1 million in the same period in 2011. While revenues for the first six months declined slightly from $36.8 million in 2011 to $36.0 million in 2012, the cost of revenues decreased 13.9 percent from $35.3 million in 2011 to $30.4 million in the comparable period in 2012.
"The cost saving measures we accomplished earlier this year, with mid-level and senior executives taking salary reductions, and some layoffs, combined with ending contracts that were not profitable for CompCare, are paying rewards. For the first six months of 2012, we were profitable, cash flow positive and were able to increase operating income and reduce our general and administrative expenses from $4.1 million in the first half of 2011 to $2.7 million for the comparable period this year," said Clark Marcus, Chairman and CEO.
"I am especially pleased that our pharmacy management contracts were up 18.9 percent, or $3.1 million, to $19.4 million in the first six months of 2012 compared to the previous year due to a 3.6 percent increase in membership and an 11 percent contract rate increase with the health plan we serve in Puerto Rico. We truly believe our strategies to reduce pharmaceutical costs for our clients will be a key element for our future growth," Mr. Marcus said.
"I am very proud of these financial results and the fact that CompCare's management team has solidified the foundation of the Company, improving it to support our growth. We have added senior level consultants with track records of success and we are dedicated to provide our shareholders continued growth in the future," Mr. Marcus concluded.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584

Published at Investorideas.com Newswire

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894